<DOC>
	<DOCNO>NCT01676649</DOCNO>
	<brief_summary>The safety combination ipilimumab carboplatin/paclitaxel treatment two different dose schedule investigate patient metastatic melanoma . This protocol also investigate clinical benefit combination feature host immune system may predict response ipilimumab chemotherapy patient unresectable Stage III Stage IV melanoma .</brief_summary>
	<brief_title>Ipilimumab With Carboplatin Paclitaxel Patients With Unresectable Stage III Stage IV Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Willing able give write informed consent . Histologic diagnosis malignant melanoma Untreated unresectable Stage III melanoma N3 macroscopic lymph node intransit/satellite metastasis Stage IV melanoma ( note prior adjuvant melanoma therapy permit ) . Prior treatment BRAF inhibitor metastatic setting also permit . Measurable/evaluable disease Required value initial laboratory test : WBC ≥ 2000/uL ANC ≥ 1.5 x 10E9/L Platelets ≥ 100 x 10E9/L Hemoglobin ≥ 90 g/L ( may transfuse ) Creatinine Clearance ≥ 50 ml/min ( calculated CockcroftGault ) AST/ALT ≤ 2.5 x ULN patient without liver metastasis , ≤ 5 time liver metastasis Bilirubin ≤ 2.5 x ULN No active chronic infection HIV , Hepatitis B , Hepatitis C. ECOG Performance status 0 1 . Men woman , ≥ 18 year age . Women childbearing potential ( WOCBP ) must use adequate method contraception avoid pregnancy throughout study 26 week last dose investigational product , manner risk pregnancy minimize . WOCBP include female experienced menarche undergone successful surgical sterilization ( hysterectomy , bilateral tubal ligation , bilateral oophorectomy ) postmenopausal . Postmenopause define : Amenorrhea ≥ 12 consecutive month without another cause , For woman irregular menstrual period take hormone replacement therapy ( HRT ) , document serum follicle stimulate hormone ( FSH ) level ≥ 35 U/L . WOCBP must negative serum urine pregnancy test ( minimum sensitivity 25 IU/L equivalent unit HCG ) within 72 hour start ipilimumab . Men father potential must use adequate method contraception avoid conception throughout study [ 26 week last doseof investigational product ] manner risk pregnancy minimize . Evidence symptomatic CNS lesion determine investigator ( patient asymptomatic lesion previously irradiate surgically resect eligible ) . Any malignancy patient diseasefree less one year , exception adequately treat basal squamous cell skin cancer , superficial bladder cancer carcinoma situ cervix . Autoimmune disease : Patients history inflammatory bowel disease , include ulcerative colitis Crohn 's Disease , exclude study , patient history symptomatic disease ( eg , rheumatoid arthritis , systemic progressive sclerosis [ scleroderma ] , systemic lupus erythematosus , autoimmune vasculitis [ eg , Wegener 's Granulomatosis ] ) ; motor neuropathy consider autoimmune origin ( e.g . GuillainBarre Syndrome Myasthenia Gravis ) . Any underlying medical psychiatric condition , opinion investigator make administration ipilimumab hazardous obscure interpretation AEs , condition associate frequent diarrhea . Patients ≥ Grade 2 peripheral neuropathy . Any nononcology vaccine therapy use prevention infectious disease ( 1 month dose ipilimumab ) . A history prior treatment ipilimumab prior CD137 agonist CTLA 4 inhibitor agonist . Concomitant therapy following : IL 2 , interferon , nonstudy immunotherapy regimen ; immunosuppressive agent ; investigation therapy ; chronic use systemic corticosteroid . Women childbearing potential ( WOCBP ) , define , : 1. unwilling unable use acceptable method contraception avoid pregnancy entire study period least 26 week cessation study drug , 2. positive pregnancy test baseline , 3. pregnant breastfeeding . Prisoners subject compulsorily detain ( involuntarily incarcerate ) treatment either psychiatric physical ( eg , infectious ) illness .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>